SCHEDULE 13G/A: ARCH Venture Funds Maintain Significant 13.1% Passive Stake in Lyell Immunopharma

ARCH Venture Fund entities and their managing directors have reported a combined passive beneficial ownership of 13.1% in Lyell Immunopharma, Inc. as of December 31, 2024.

Summary

• ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., and related entities, along with managing directors Keith Crandell, Clinton Bybee, and Robert Nelsen, collectively reported beneficial ownership of Lyell Immunopharma, Inc. common stock.
• As of December 31, 2024, the group beneficially owned an aggregate of 36,597,716 shares, representing 13.1% of Lyell Immunopharma's outstanding common stock.
• This percentage is based on 279,220,614 shares of common stock outstanding as of November 5, 2024, as reported in Lyell Immunopharma's Form 10-Q filed on November 7, 2024.
• Robert Nelsen's beneficial ownership includes 185,000 shares from vested options.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating an update to a previously reported passive stake.

Sentiment

Score: 6

Explanation: The filing is a routine Schedule 13G amendment reporting a significant passive ownership stake by ARCH Venture entities in Lyell Immunopharma. While it doesn't contain new operational or financial data, the continued substantial investment by a prominent life sciences venture capital firm can be interpreted as a positive signal of long-term confidence in the company's prospects.

Positives

• Continued significant ownership by ARCH Venture, a prominent venture capital firm specializing in life sciences, may signal ongoing confidence in Lyell Immunopharma's long-term prospects and strategic direction.

Future Outlook

NA

Industry Context

This filing indicates a significant, passive investment by a major venture capital firm (ARCH Venture) in a biotechnology company (Lyell Immunopharma). This is typical for early-stage or growth-stage biotech companies where venture capital plays a crucial role in funding and strategic guidance. The continued large stake suggests ARCH's long-term commitment to the biotech sector and specifically to Lyell's therapeutic development.

Comparison to Industry Standards

• ARCH Venture Partners is a well-known venture capital firm with a strong focus on life sciences and biotechnology, having invested in numerous successful biotech companies. Their continued significant stake in Lyell Immunopharma aligns with their strategy of supporting innovative companies in the sector.
• A 13.1% stake is a substantial passive position, indicating a significant conviction in Lyell's potential, though it does not imply active control or management influence beyond what is typical for a large institutional investor.
• This type of filing is common for venture capital firms maintaining large, passive stakes in their portfolio companies post-IPO, demonstrating long-term support rather than immediate exit.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional shareholder's stake, which can influence investor perception and potentially liquidity.
• Management: Awareness of a large, passive shareholder, though typically without direct operational impact.

Key Dates

Recommendation

Keywords

Lyell Immunopharma, ARCH Venture, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Healthcare, Investment, Passive Stake, SEC Filing